Chemotherapy-induced Neutropenia
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Neutropenia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-24EMA Authorised: Grasustek (pegfilgrastim) — Juta Pharma GmbH
EMA authorised Grasustek (pegfilgrastim) for marketing by Juta Pharma GmbH; decision date 24 March 2026.
-
EMA approval · 2026-03-18EMA Authorised: Cegfila (previously Pegfilgrastim Mundipharma) (pegfilgrastim) — Mundipharma Corporation (Ireland) Limited
The EMA authorised the pegfilgrastim product Cegfila (Mundipharma) for marketing in the European Union.
-
EMA approval · 2026-03-18EMA Authorised: Pelmeg (pegfilgrastim) — Mundipharma Corporation (Ireland) Limited
EMA authorised Pelmeg, a pegfilgrastim biosimilar by Mundipharma, to reduce the duration of neutropenia and the risk of febrile neutropenia …
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: G-CSF-Induced Bone Pain and Supportive Care Approaches
This Clinical Trial Update discusses strategies to manage G-CSF-induced bone pain and evaluates supportive care approaches in a completed tr…
-
EMA approval · 2026-02-19EMA Authorised: Fulphila (pegfilgrastim) — Biosimilar Collaborations Ireland Limited
EMA authorised Fulphila, a pegfilgrastim biosimilar by Biosimilar Collaborations Ireland Limited. The approval covers its use to reduce the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-20EMA Authorised: Nyvepria (pegfilgrastim) — Pfizer Europe MA EEIG
EMA has authorised Nyvepria (pegfilgrastim) for use as a pegfilgrastim product. It is indicated to reduce the duration of chemotherapy-induc…
-
FDA approval · 2025-11-28FDA Approved: ARMLUPEG — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved ARMLUPEG (pegfilgrastim-unne) from Lupin Pharmaceuticals in an Original Biologics License Application. Pegfilgrastim-unne is a …
-
EMA approval · 2025-11-25EMA Authorised: Accofil (filgrastim) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Accofil, a filgrastim biosimilar from Accord Healthcare S.L.U., for EU marketing to prevent chemoth…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
Clinical trial update indicates telpegfilgrastim injection is being studied to reduce chemotherapy-induced neutropenia in patients with soli…
-
EMA approval · 2025-07-08EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
The EMA authorised Zarzio, a filgrastim biosimilar from Sandoz GmbH, for use in hematopoietic stem cell transplantation and cancer indicatio…
-
CLINICAL_TRIALS research · 2025-05-25Clinical Trial Update: Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia [Phase 4]
This Phase 4 clinical trial compares adding G-CSF to antibiotics versus antibiotics alone for resolving febrile neutropenia; the study statu…
-
FDA approval · 2025-04-18FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for NEUPOGEN (filgrastim) by Amgen, Inc.
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors [Phase 2]
Phase 2 clinical trial update comparing telpegfilgrastim with filgrastim for secondary prevention of chemotherapy-induced neutropenia in ped…
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Breath Analysis for the Detection of Invasive Fungal Infections
This clinical trial update describes a breath analysis approach being studied to detect invasive fungal infections in patients with leukemia…
-
FDA approval · 2025-03-26FDA Approved: STIMUFEND — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for STIMUFEND (PEGFLILGRASTIM-FPGK) from Fresenius Kabi USA, LLC, expanding/confirming labeling to s…
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy [Phase 2]
Phase 2 study evaluating the safety, efficacy, and pharmacokinetics of Telpegfilgrastim in pediatric cancer patients with chemotherapy-induc…
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim
A completed clinical trial compared patient preferences between a prefilled syringe and a prefilled pen for administering pegfilgrastim.
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. [NA]
A multi-cohort clinical trial evaluating Efbemalenograstim Alfa Injection to prevent ANC reduction in solid tumor patients following immune-…
-
CLINICAL_TRIALS trial_result · 2024-08-29Clinical Trial Update: Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 [Phase 3]
Phase 3 trial comparing Plinabulin to Pegfilgrastim in patients with solid tumors receiving docetaxel-based myelosuppressive chemotherapy ha…
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 [Phase 2]
Phase 2 trial comparing plinabulin to pegfilgrastim in patients with solid tumors receiving docetaxel-based chemotherapy for chemotherapy-in…
-
FDA approval · 2023-10-09FDA Approved: ZIEXTENZO — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for ZIEXTENZO (pegfilgrastim-bmez) filed by Sandoz Inc, indicating a labeling update or indicati…
-
FDA approval · 2023-09-01FDA Approved: RELEUKO — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for RELEUKO (filgrastim) submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2023-08-28FDA Approved: NIVESTYM — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for NIVESTYM (filgrastim-aafi) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel [Phase 3]
Phase 3 trial evaluating Neugranin in breast cancer patients receiving doxorubicin/docetaxel for chemotherapy-induced neutropenia has comple…
-
FDA approval · 2023-03-03FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)
The FDA approved a supplemental application for UDENYCA (pegfilgrastim-cbqv) by Accord BioPharma, Inc., to update the product labeling.